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IMPAK UBAT-UBAT PENCEGAH DAN FAKTOR BERKAITAN STROK 
ISKEMIA TERHADAP HASIL RAWATAN: KAEDAH MULTIMODEL 
PENGUBATAN PENCEGAHAN 
 
 
ABSTRAK 
Strok iskemia akut adalah satu masalah kesihatan global dan merupakan antara punca 
utama morbiditi dan mortaliti. Oleh kerana pencegahan dianggap sebagai teras utama 
pengurusan strok iskemia akut, pengetahuan tentang bukti saintifik perlu  ditekankan  
di sebalik penggunaan ubat-ubatan pencegahan dan  kesannya keatas hasil rawatan 
pesakit. Objektif kajian adalah untuk mengkaji impak penggunaan terdahulu perencat 
enzim penukar-angiotensin (angiotensin-converting enzyme inhibitor [ACEI]), 
antiplatelet dan statin, sama ada secara bersendirian atau dalam kombinasi, terhadap 
mengurangkan kadar mortaliti di hospital, meningkatkan status fungsi sewaktu 
keluar hospital dan mengurangkan komplikasi selepas strok iskemia. Di samping itu, 
faktor-faktor lain yang dikaitkan dengan berlakunya hasil rawatan strok iskemia 
tersebut juga diselidiki.  
Kajian pemerhatian dengan reka bentuk kohort retrospektif digunakan bagi semua 
pesakit strok iskemia yang dimasukkan ke Hospital Pulau Pinang dalam tempoh 
bermula dari 1 Januari 2008 sehingga 30 Jun 2009. Data termasuk ciri-ciri sosio-
demografik, ciri-ciri klinikal, dan kelas ubat-ubatan terdahulu, dengan perhatian 
khusus diberikan kepada antiplatelet, ACEI dan statin. Impak penggunaan terdahulu 
ubat-ubatan tersebut terhadap hasil rawatan strok iskemia termasuklah: kadar 
mortaliti di hospital, status fungsi yang baik seperti yang ditakrifkan oleh Indeks 
Barthel (BI) > 75, dan komplikasi pasca-strok, telah dinilai selepas mengawal lain-
lain pembolehubah (iaitu sosio-demografik, ciri-ciri klinikal, faktor-faktor risiko dan 
ubat-ubatan lain) yang mungkin mempengaruhi kesan ubat-ubatan pencegahan itu 
terhadap kesudahan strok iskemia. 
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Secara keseluruhannya, 854 orang pesakit telah memenuhi kriteria penyertaan. 
Selepas mengawal semua pembolehubah yang mungkin mempengaruhi; penggunaan 
terdahulu ACEI secara bersendirian atau dalam kombinasi dengan antiplatelet 
dan/atau ubat-ubatan statin didapati mengurangkan risiko mortaliti dengan ketara 
semasa dirawat di hospital, dengan peluang tertinggi dalam mengurangkan mortaliti 
adalah dalam kalangan pesakit yang menggunakan kombinasi tiga-ubat. Selain itu, 
dalam kalangan mangsa strok yang terselamat, kombinasi dua-ubat “antiplatelet dan 
ACEI”, “antiplatelet dan statin”, atau “ACEI dan statin”, atau kombinasi tiga-ubat 
boleh meningkatkan kemungkinan keluar dari hospital dengan status fungsi yang 
baik sebanyak kira-kira lima kali lebih tinggi berbanding dengan pesakit yang tidak 
mengambil ubat-ubatan pencegahan, dan mempunyai kemungkinan yang lebih baik 
berbanding pesakit yang hanya mengambil satu ubat daripada kumpulan-kumpulan 
berbeza.  Tambahan pula, peluang lebih tinggi untuk mengurangkan risiko 
komplikasi pasca-strok didapati ketara dalam kalangan pesakit yang telah 
menggunakan ACEI. Penggunaan ACEI dan statin secara kombinasi, dan kombinasi 
tiga-ubat, secara ketara mempunyai kemungkinan yang tertinggi dalam 
mengurangkan terjadinya komplikasi. Berlakunya mortaliti di hospital, keluar 
hospital dengan status fungsi yang baik, atau pendedahan kepada komplikasi pasca-
strok, mungkin boleh diramal daripada ciri-ciri klinikal yang spesifik, tanda-tanda 
penting semasa dimasukkan ke hospital, faktor-faktor risiko, dan tidak menggunakan 
ubat-ubatan pencegahan. 
Kami menyimpulkan bahawa kemungkinan tertinggi bagi menambahbaik hasil 
fungsi dan mengurangkan kadar mortaliti serta komplikasi selepas strok iskemia  
diperhatikan pada pesakit yang mengambil kombinasi tiga-ubat antiplatelet, ACEI 
dan statin. Hasil kajian kelihatan mengesahkan penggunaan kombinasi ini dalam 
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individu-individu yang berisiko dan dalam pesakit yang didiagnos dengan strok 
iskemia dan juga untuk memulakan terapi kombinasi lebih awal selepas strok bagi 
memperbaiki hasil rawatan iskemia strok. Selain itu, peningkatan pengetahuan 
mengenai faktor-faktor bebas yang paling prediktif kepada hasil rawatan strok 
iskemia akut boleh membantu pengamal perubatan mengenalpasti pesakit-pesakit 
berisiko tinggi  mengalami morbiditi dan mortaliti, dan seterusnya mungkin boleh 
mempengaruhi keputusan-keputusan pengurusan.  
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THE IMPACT OF PREVENTIVE MEDICATIONS AND FACTORS 
RELATED TO ACUTE ISCHEMIC STROKE ON OUTCOMES: 
MULTIMODAL PREVENTIVE MEDICATION APPROACH 
 
ABSTRACT 
 
Acute ischemic stroke is a global health problem and is among the leading causes of 
morbidity and mortality. As prevention is considered the mainstay of management for 
acute ischemic stroke, knowledge should be highlighted regarding the scientific 
evidence behind the use of preventive medications and their impact on patients’ 
outcomes. The objective of the study is to evaluate the impact of the previous use of 
angiotensin-converting enzyme inhibitor (ACEI), antiplatelet and statin, either alone 
or in combinations on reducing in-hospital mortality rates, improving functional status 
at discharge and reducing complications after ischemic stroke. In addition, the 
independent factors associated with the occurrence of these ischemic stroke outcomes 
have been investigated.  
An observational retrospective cohort design was used for all acute ischemic stroke 
patients admitted to Hospital Pulau Pinang during the period from January 1st 2008 to 
June 30th 2009. Data included socio-demographic characteristics, clinical 
characteristics, and previous medication classes, with particular attention being paid to 
antiplatelets, ACEIs and statins. Impact of the previous use of these medications on 
ischemic stroke outcomes included: the in-hospital mortality rate, a good functional 
status as defined by the Barthel Index (BI) > 75, and post-stroke complications, was 
evaluated after controlling for other variables (i.e. socio-demographic, clinical 
characteristics, risk factors and other medications) that might have confounded the 
effects of these preventive medications on ischemic stroke outcomes.  
Overall, 854 patients met the inclusion criteria. After controlling for possible 
confounders; the previous use of ACEI alone or in combination with antiplatelet 
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and/or statin medications was found to significantly reduce the risk of mortality during 
hospitalization, with the highest chance in reducing the mortality was among patients 
using the three-medication combination. In addition, among the stroke survivors, the 
two-medication combinations of “antiplatelet and ACEI”, “antiplatelet and statin”, or 
“ACEI and statin”, or the three-medication combination can increase the odds of 
discharge with a good functional status by approximately five times higher compared 
to patients who did not take preventive medications, and having higher odds compared 
to patients who took only one medication from different groups. Moreover, high 
chances of reducing the risk of post-stroke complications were significantly observed 
among the patients who were on ACEI. The use of ACEI and statin in combination, 
and the three-medication combination, had significantly the highest odds in reducing 
the occurrence of complications. The occurrence of in-hospital mortality, being 
discharged with good functional status, or the exposure to post-stroke complications, 
might be predicted from specific clinical characteristics, vital signs on admission, risk 
factors, and the non-use of preventive medications.   
We conclude that the highest odds of improving functional outcome and reducing the 
rates of mortality and complications after ischemic stroke were observed in patients 
who were taking the three-medication combination of antiplatelet, ACEI and statin. 
The finding appear to endorse the use of this combination in individuals at risk and in 
patients diagnosed with ischemic stroke and for the early initiation of this combination 
therapy after stroke to improve ischemic stroke outcomes. Additionally, an increased 
knowledge of the most predictive variables of acute ischemic stroke outcomes can 
assist clinicians in identifying patients at higher risk of morbidity and mortality, and 
thus may influence management decisions.   
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Stroke: general background  
 
Stroke (cerebrovascular disease) is a syndrome with several pathologies (Mant and 
Walker, 2011). The father of medicine, Hippocrates (460 to 370 BC), was the first to 
describe the event of sudden paralysis that is often associated with ischemia. In his 
writings, he used the word “apoplexy”, a Greek word that means “struck down with 
violence”, to describe the stroke event. The word “stroke” was used as a synonym for 
apoplectic seizure in approximately 1599. Later, in 1658, Johann Jacob Wepfer 
(1620-1695) identified the cause of hemorrhagic stroke when he suggested that 
people who had died because of apoplexy had a hemorrhage in their brains. Wepfer 
also identified the vertebral and carotid arteries, which are the main arteries 
supplying the brain, and the cause of ischemic stroke when he suggested that 
apoplexy might be caused by a blockage in these vessels (Gerber, 2003; Nilsen, 
2010). 
 
1.1.1 Stroke: background and global disease burden 
 
Stroke is a global health problem and it is among the leading causes of morbidity and 
mortality worldwide. Annually, about 16 million first-ever strokes occur worldwide, 
with a death toll of approximately 5.7 million people per year (Strong et al., 2007). 
Approximately more than half of all strokes occur in people older than 75 years of 
age, and although the incidence of stroke is declining in many developed countries, 
largely as a result of better risk factor control, the absolute number of strokes 
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continues to increase because populations are living longer (Brainin et al., 2007; 
Feigin et al., 2009).  In addition, when stroke is considered separately from other 
cardiovascular diseases, it is ranked as the third most common cause of death behind 
heart diseases and cancer (Lloyd-Jones et al., 2010). In addition, mortality data from 
2006 indicated that stroke accounted for approximately 1 out of every 18 deaths in 
the United States of America (USA) during that year (Lloyd-Jones et al., 2010). 
Furthermore, stroke is the leading cause of serious, long-term disability, which not 
only has a serious physical and emotional burden on the people affected, but also 
places a large economic burden on society (Lloyd-Jones et al., 2010). Furthermore, 
stroke has dire consequences on patients, relatives and society and is associated with 
a vast economic burden. In the United Kingdom (UK) and other countries, stroke-
related costs are on the rise and consistently consume around 5% of health-care 
resources (Martinez-Vila and Irimia, 2004). In the USA, the total estimated direct 
and indirect costs of stroke in 2010 came to $73.7 billion (Lloyd-Jones et al., 2010).  
 
Following the initial stroke, many patients suffer a further stroke, and recurrent 
strokes account for approximately 25% of stroke events, and it has been found that 
almost 1 in 10 hospitalized ischemic stroke patients was readmitted for a recurrent 
ischemic stroke within 1 year (Allen et al., 2010). On the other hand, between 15 and 
30% of stroke patients were found to have a history of transient ischemic attack 
(TIA) (Rothwell and Warlow, 2005); following TIA, the seventh-day risk of stroke 
can exceed 30% in high risk groups (Rothwell et al., 2005b). Recent studies 
recommended the prompt evaluation and treatment of patients with TIA, as this can 
lower the expected risk of subsequent stroke events (Gallego et al., 2009). 
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1.1.2 Stroke: the Malaysian situation 
 
In 2002, the World Health Organization (WHO) reported that approximately 60% of 
the world’s total mortality from stroke occurred in the East Asian region, which 
comprises South East Asia and the Western Pacific regions (WHO, 2004). In 2004, a 
study on disease burden using disability-adjusted life years (DALY) showed that the 
five leading diseases in Malaysia, in decreasing order, are ischemic heart disease 
(IHD), mental illness, cerebrovascular disease/stroke, road traffic injuries and cancer 
(WHO-Malaysia, 2009). 
 
Furthermore, chronic non-communicable diseases and injuries are the leading causes 
of death in Malaysia. The Health Facts 2009 report showed that the leading causes of 
mortality in Ministry of Health (MOH) hospitals are heart diseases and pulmonary 
circulation diseases (ranked first), septicaemia (ranked second), malignant neoplasms 
(ranked third), pneumonia (ranked fourth) and cerebrovascular diseases (ranked fifth) 
(MOH Malaysia, 2010). In addition, the WHO statistical report of the level of 
mortality and the burden of diseases in the year 2004 showed that the number of 
deaths from cerebrovascular diseases in Malaysia was 43.2 per 100,000 population 
(WHO, 2009). Additionally, the third quarter 2010 Penang Statistical Report showed 
that cerebrovascular disease/stroke was the fourth principal cause of death in Penang 
Government Hospitals, with 366 (13.54%) deaths attributed to this cause in the year 
2009 (SERI, 2010). 
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1.2 Definition of stroke 
 
A stroke is defined by the WHO as a syndrome of rapidly developing clinical 
symptoms and/or signs of focal (or at times global) disturbance of cerebral 
functioning lasting more than 24 hours (unless interrupted by surgery or death), with 
no apparent cause other than being of vascular origin (Donnan et al., 2008). This can 
be due to ischemia or hemorrhage (intracerebral hemorrhage or subarachnoid 
hemorrhage) (Warlow et al., 2001). Ischemia results from an interruption of the 
blood supply, whereas a hemorrhage results from the rupture of a blood vessel or an 
abnormal vascular structure. Of all strokes, 87% are ischemic, 10% are intracerebral 
hemorrhage and 3% are subarachnoid hemorrhage strokes (Lloyd-Jones et al., 2010).  
 
1.3 Pathophysiology of acute ischemic stroke 
 
1.3.1 Mechanisms of ischemia  
 
There are many etiologic mechanisms for acute ischemic stroke; however, the 
common pathway is the lack of sufficient blood flow to perfuse cerebral tissue that 
can lead to irreversible neuronal damage (Deb et al., 2010). Ischemic stroke can 
manifest in the form of thrombotic stroke (large vessel and small vessel types), 
embolic stroke, systemic hypoperfusion or venous thrombosis (Donnan et al., 2008; 
Deb et al., 2010).  
 
Thrombotic stroke is the most common type and occurs when a thrombus blocks the 
blood flow to parts of the brain. In large vessel thrombosis, the luminal part of 
atheromatous plaques may be degraded by metalloproteinases, leading to rupture and 
forming an ulcerated lesion with highly thrombogenic properties (Ay, 2010). In small 
vessel thrombosis, microatheromatosis results in lacunar infarcts, and in vessels less 
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than 200 micrometer in diameter the small lacunar infarcts formed are often 
asymptomatic (Labovitz et al., 2007). Additionally, patients who develop heparin-
induced thrombocytopenia due to abnormal antibody formation that leads to platelets 
activation (Salem et al., 2010), thrombotic thrombocytopenic purpura (Lindblom et 
al., 2009; Tsai, 2009) and patients with a hypercoaguable autoimmune 
antiphospholipid antibody syndrome in which antibodies are formed against the cell 
membrane phospholipids (Camargo et al., 2011) may be at increased risk for both 
venous and arterial thrombosis. 
 
On the other hand, embolic stroke occurs when an embolus carried by the 
bloodstream to the brain, where the larger arteries branch off into smaller vessels. 
This blood clot reaches a point where it cannot move further and effectively plugs a 
small cerebral artery, cutting off the blood supply to the brain (Allen and 
Bayraktutan, 2008; Massicotte and Bauman, 2011). Heart is the main source of the 
emboli that may reach the brain. Left atrial thrombus, left ventricular thrombus, atrial 
fibrillation (AF), sick sinus syndrome, sustained atrial flutter, rheumatic mitral or 
aortic valve disease, myocardial infarction (MI), infective or nonbacterial thrombotic 
endocarditis are examples of high risk sources for cerebral emboli (Doufekias et al., 
2008). 
 
Systemic hypoperfusion is another main mechanism of ischemic stroke, which 
occurs due to a generalized loss of arterial pressure. The area of brain that tends to be 
predominantly affected is that called watershed region which is located at the most 
distal edges of the arterial tree of the main cerebral artery territories (Deb et al., 
2010). Additionally, another mechanism of ischemic stroke is cerebral venous 
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thrombosis that can lead to vascular congestion, impairment of forward flow, and 
eventually infarction (Vembu et al., 2011).  
 
1.3.2 Cellular pathophysiology 
 
Low respiratory reserve and complete dependence on aerobic metabolism make the 
brain tissue particularly vulnerable to a compromised vascular supply to the brain 
that is called ischemia (Deb et al., 2010). The brain’s response to acute ischemia 
depends on the severity and duration of compromised vascular supply. It has been 
suggested that there are different ischemic thresholds for cerebral dysfunction and 
cell death. When blood flow drops from the normal value of 50 to 55 ml/100 
gram/minute to about 18 ml/100 gram/minute, the brain has reached the threshold for 
synaptic transmission failure, however, these cells have the potential for recovery. 
Then, when blood flow drops to about 8 ml/100 gram/minute, cell death can result 
(Bandera et al., 2006; Braeuninger and Kleinschnitz, 2009). However, due to the 
presence of collateral circulation, different degrees of severity can be observed in the 
affected region of the brain. Consequently, part of the brain parenchyma named the 
“core”, undergoes immediate death, while other parts, the “penumbra”, may be 
partially injured but still have the potential to recover (Deb et al., 2010).  
 
On the cellular level, the local depletion of oxygen or glucose leads to a failure of the 
mitochondria to produce high-energy phosphate compounds, such as adenosine 
triphosphate (ATP) that can trigger cell death. Although this energy failure does not 
immediately precipitate cell death, 5 to10 minutes of complete occlusion can lead to 
irreversible brain injury, and even a partial occlusion for a prolonged period can 
cause harmful effects (Karaszewski et al., 2009). Furthermore, as approximately 
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70% of the metabolic demand in the brain is due to the Na+/K+ ATPase pump that 
maintains the ion gradient responsible for neuronal membrane potential, an 
inadequate energy supply leads to malfunctioning of the ion gradient, which results 
in a loss of potassium in exchange for sodium, chloride and calcium ions (Lo et al., 
2003; Deb et al., 2010). This is accompanied by an inflow of water, resulting in rapid 
swelling of neurons and glia leading to cytotoxic edema (Kim et al., 2011). An 
ischemic cascade also stimulates the release of excitatory neurotransmitters in the 
brain. An uncontrolled release of glutamate in ischemic area, for example, enhances 
the excitotoxic synaptic transmission that leads to further sodium and calcium ion 
influxes, which uses the already depleted ATP to maintain a calcium balance, and the 
disordered activation of protease, lipase, and nuclease enzymes ultimately leading to 
cell death (Lo et al., 2003; Henson et al., 2010), (Figure 1.1). 
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Figure 1.1: Major pathways implicated in ischemic cell death. (After ischemic onset, 
loss of energy substrates leads to mitochondrial dysfunction and the generation of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS). Additionally, energy deficits lead to ionic 
imbalance and excitotoxic glutamate efflux and build up of intracellular calcium. Downstream 
pathways ultimately include direct free radical damage to membrane lipids, cellular proteins, and 
deoxyribonucleic acid (DNA)  
(Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev Neurosci] (Lo et al.,), copyright 
(2003). 
 
On the other hand, an ischemic cascade also activates neuroprotective mechanisms as 
a defence against cell death (Liu et al., 2009). The first protein to be released after 
ischemia is heat shock protein 70 (HSP70), and its messenger ribonucleic acid 
(mRNA) is expressed within 1 to 2 hours of ischemia. Studies on animals showed, 
that the HSP70 inducer is efficacious in limiting the infarct volume, and inhibiting 
monocyte/macrophage activation (Giffard and Yenari, 2004; Liu et al., 2009). 
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Other neuroprotective mechanisms may be activated to compensate the effects of 
ischemia. Anti-apoptotic B-cell lymphoma 2 (Bcl-2) gene family members suppress 
the release of sequestered proteins and modulate calcium fluxes (Thomenius et al., 
2003). The prion protein may have a neuroprotective effect, it is up-regulated during 
hypoxia, and inhibits neuronal cell death (Weise et al., 2006). In addition, 
neurotrophin-3 is the growth factor that is especially essential for the survival and 
maintenance of neurons, and its expression could play a role in neuronal survival 
after brain ischemia (Galvin and Oorschot, 2003).  Interleukin-10 gene is another 
neuroprotective mechanism, its expression is elevated in most central nervous system 
diseases and aids in neuronal and glial cell survival via blocking the effects of pro-
inflammatory cytokines and by promoting the expression of cell survival signals 
(Strle et al., 2001).  
 
1.4 Classification, clinical diagnosis and syndromes of acute ischemic stroke 
 
Acute ischemic stroke classifications are largely based on clinical findings and 
pathophysiology. The most common schemes that have been developed to classify 
subtypes are the Trial of Org 10172 in Acute Stroke Treatment (TOAST) and the 
Oxfordshire Community Stroke Project (OCSP). 
 
The TOAST classification system is mainly based on the etiology of the attack and 
includes five categories (Jackson and Sudlow, 2005; Kirshner, 2009). Moreover, the 
diagnoses are based on clinical features and on data collected by tests such as brain 
imaging by computed tomography (CT) or magnetic resonance imaging (MRI), 
cardiac imaging (echocardiography), duplex imaging of extracranial arteries, 
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arteriography, and laboratory assessments for a prothrombotic state  (Adams et al., 
1993); (Table 1.1). 
 
Table 1.1. TOAST classification scheme of acute ischemic stroke 
 
 
Subtype 
classification 
 
Subtype classification criteria 
Large artery 
atherosclerosis 
- Cortical, cerebellar, or brain stem dysfunction. 
- Cortical, cerebellar, or brain stem lesions > 1.5 cm upon brain 
imaging. 
- Diagnosis supported by > 50% stenosis of a major brain 
artery or branch cortical artery upon angiography or duplex 
imaging. 
- History of TIA in the same vascular territory, and/or 
exclusion of a cardioembolic source. 
 
Cardioembolism 
 
- Cortical, cerebellar, or brain stem dysfunction. 
- Cortical, cerebellar, or brain stem lesions > 1.5 cm upon brain 
imaging. 
- Identified source of cardioembolism (e.g., AF or valvular 
disease). 
- Previous TIAs in > 1 vascular territory. 
 
Lacunar 
 
- No evidence of cortical dysfunction. 
- Cortical, cerebellar, or brain stem lesions < 1.5 cm upon brain 
imaging. 
- Less than 50% stenosis of major brain artery or branch 
cortical artery upon angiography or duplex imaging. 
- Known lacunar syndrome. 
- History of diabetes or hypertension 
 
Other 
determined 
aetiology 
- Diagnosed nonatherosclerotic vasculopathy, hypercoagulable 
state, or hematologic disorder. 
 
 
Undetermined 
aetiology 
 
- Inability to classify after extensive evaluation. 
- Evidence of ≥  2 stroke subtypes (e.g., AF and stenosis > 
50%). 
 
Abbreviations: AF: Atrial fibrillation; TIA: Transient Ischemic Attack; TOAST: Trial of Org 10172 
in Acute Stroke Treatment. 
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In addition, acute ischemic strokes are also categorized according to the OCSP 
classification system. The OCSP classification depends on the signs and symptoms 
present at the time of maximal deficit after a stroke attack, and it includes total 
anterior circulation infarct (TACI), partial anterior circulation infarct (PACI), lacunar 
infarct (LACI), and posterior circulation infarct (POCI) (Bamford et al., 1991; 
Jackson and Sudlow, 2005). Additionally, this classification is a reasonably valid 
way of predicting the site and size of cerebral infarction, the functional recovery and 
rates of fatality after an attack. Therefore, it can be used very early after ischemic 
stroke onset, before the infarct appears on the scan (Bamford et al., 1991); (Table 
1.2).  
Table 1.2. OCSP classification scheme of acute ischemic stroke 
 
Subtype 
classification 
Subtype classification criteria 
TACI - Charaterized by hemiparesis, dysphasia, and homonymous 
hemianopia. 
- Large cortical MCA infarct or > 50% of the MCA territory 
plus ACA or PCA territory. 
- Subcortical infarct > 1.5 cm 
 
PACI 
 
- Presentation with 2 of the following: hemiparesis, dysphasia, 
or homonymous hemianopia. 
- Isolated dysphagia. 
- Cortical MCA infarct < 50% of the MCA territory. 
- Border zone cortical infarct between ACA and MCA or PCA 
and MCA territories. 
  
LACI 
 
- Pure motor stroke, pure sensory stroke, sensorimotor stroke, 
or ataxic hemiparesis. 
- Subcortical infarct < 1.5 cm. 
 
POCI 
 
- Brainstem or cerebellar dysfunction and/or isolated 
homonymous hemianopia. 
- Cortical infarct in PCA territory. 
- Brainstem or cerebellar infarct. 
 
 
Abbreviations: ACA: anterior cerebral artery; LACI: lacunar infarct; MCA: middle cerebral artery; 
OCSP: Oxfordshire Community Stroke Project; PACI: Partial anterior cerebral infarct; PCA: posterior 
cerebral artery; POCI: posterior circulation infarct; TACI: total anterior circulation infarct. 
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Ischemic stroke clinical symptoms depend on the area of the brain and the arterial 
territories affected (Figure 1.2). It is usually present with an acute loss of brain 
functions; these functions usually involve the area of motor, sensory, language, 
vision, visuo-spatial perception or consciousness. And the common signs of stroke 
include: acute hemiparesis or hemiplegia, acute hemisensory loss, complete or partial 
hemianopia, monocular or binocular visual loss, or diplopia, dysarthria or aphasia, 
ataxia, vertigo, or nystagmus, and sudden decrease in consciousness (Blumenfeld, 
2002). 
 
 
Figure 1.2. Major vascular territories of the brain and important anatomic 
structures.  
Abbreviations: ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA:  posterior cerebral 
artery.  
(Adapted with permission from Blumenfeld HJ. Neuroanatomy through clinical cases. Sunderland 
[MA]: Sinauer Associates; 2002:375).  
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Motor weakness is the most frequent clinical manifestation of ischemic stroke. About 
two thirds of patients present with uniform hemiparesis involving face, hand, 
shoulder, foot, and hip. In addition, monoplegia, which occurs in approximately 19% 
of strokes, usually indicates small infarcts of the motor cortex or centrum semiovale. 
In majority of cases, faciobrachial weakness is caused by superficial middle cerebral 
artery (MCA) infarcts, and distal hemiparesis indicates cortical involvement 
(Blumenfeld, 2002). Furthermore, sensory abnormalities are the second most 
frequent manifestation of stroke that occur in 50% of stroke patients, and involve the 
hemiface, arm, trunk, and leg. Stroke is the most common cause of pure sensory loss. 
In addition, cortical strokes typically produce impairment of discriminative 
sensations with relative preservation of protopathic sensations (Sullivan and 
Hedman, 2008). Dysarthria occurs in nearly 8.7% of ischemic strokes. Pure 
dysarthria is frequently associated with cortical lesions, whereas dysarthria with 
other neurological signs is more frequently caused by pontine involvement (Kumral 
et al., 2007).  
 
1.5 Risk factors of acute ischemic stroke 
Many risk factors have been identified for ischemic stroke that are associated with an 
increased risk of stroke attack. They are classified into modifiable and non-
modifiable risk factors (Goldstein et al., 2011), (Table 1.3). Modifiable risk factors 
include those resulting from lifestyle changes and the environment, which can be 
modified with the help of health-care professionals, treatment and continuing 
education. On the other hand, non-modifiable risk factors include factors that are 
related to hereditary or natural processes, which cannot be modified with the current 
technology and knowledge (Allen and Bayraktutan, 2008; Goldstein et al., 2011). 
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Table 1.3 Modifiable and non-modifiable risk factors for ischemic stroke 
 
Modifiable risk factors 
 
 
Non-modifiable risk factors 
Well-documented 
- Hypertension 
- Diabetes mellitus  
- Dyslipidemia 
- Ischemic heart disease 
- Heart failure 
- Asymptomatic carotid stenosis 
- Atrial fibrillation 
- Peripheral artery disease 
- Sickle cell disease 
- Renal impairment 
- Left ventricular hypertrophy 
- Postmenopausal hormone therapy 
- Obesity 
- Cigarette smoking 
 
Less well-documented 
- Alcohol abuse 
- Hyperhomocysteinemia 
- Hypercoagulability 
- Elevated Lipoprotein(a) 
- Elevated vWF 
- Oral contraceptive pills 
- Inflammation (e.g elevated CRP) 
 
- Age 
- Gender 
- Race 
- Family history of stroke/TIA 
Abbreviations: CRP: C-reactive protein; TIA: Transient ischemic attack; vWF: Von Willebrand 
factor. 
 
1.5.1 Modifiable risk factors 
  
1.5.1.1 Hypertension 
  
Hypertension is the most prevalent modifiable risk factor for cerebral infarction. 
Arterial hypertension can result in multiple target organ damage and promotes 
atherosclerotic macroangiopathy, ensuing ischemic stroke; however, its treatment 
substantially reduces the risk of stroke (Fields et al., 2004). The Framingham Heart 
Study found that the prevalence of hypertension is high and increasing, and that 
people who are normotensive at the age of 55 years have a 90% lifetime risk of 
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developing hypertension (Vasan et al., 2002). Furthermore, more than two thirds of 
people older than 65 years of age are hypertensive (Chobanian et al., 2003). 
 
The relationship between blood pressure and stroke risk is strong, continuous, 
graded, independent, predictive and etiologically significant (Chobanian et al., 
2003). Furthermore, over the range of 115/75 to 185/115 mm Hg, each 20-mm Hg 
elevation in systolic blood pressure (or 10-mm Hg elevation in diastolic blood 
pressure) was found to roughly double the risk of death from stroke (Dahlof, 2008).  
 
1.5.1.2 Diabetes mellitus 
 
Diabetes mellitus (DM) is a clear risk factor for ischemic stroke. The risk of stroke is 
increased by 2- to 6- fold in patients with DM compared to non-diabetic individuals 
(Sander and Kearney, 2009). Case-controlled studies have shown that the odds ratio 
of lacunar stroke is increased by 2.3-fold in diabetic patients (You et al., 1995). 
Diabetes mellitus not only significantly increases the risk of stroke, but it also affects 
outcomes following ischemic stroke. Diabetes mellitus also doubles the risk of stroke 
recurrence, which usually results in a poor outcome than the first stroke, and 
increases the risk of mortality after a stroke attack (Harmsen et al., 2006; Hu et al., 
2006). In addition, approximately 20-40% of patients admitted with acute stroke are 
hyperglycemic. Some of them are known to be diabetic but a further 25-50% of 
patients have previously undiagnosed glucose tolerance abnormalities (Allen and 
Bayraktutan, 2008). 
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Moreover, stroke risk can be reduced in patients with diabetes. In the Steno-2 Study, 
patients with type 2 DM who are at high risk of vascular diseases; intensive 
intervention with multiple drug combinations of statin, angiotensin converting 
enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), or antiplatelet drug 
as appropriate and behaviour modification showed sustained beneficial effects with 
regards to vascular complications.  In addition, this intensive therapy was associated 
with a 57% lower risk of death from cardiovascular causes (Gaede et al., 2008). 
 
1.5.1.3 Ischemic heart disease 
 
In the Atherosclerosis Risk in Communities study, a history of IHD was a risk factor 
for non-lacunar (6.5%) and cardioembolic strokes (5.8%) (Ohira et al., 2006b). In 
addition, the risk of ischemic stroke has been found to gradually increase with 
increasing numbers of carotid plaques and an increase in the thickness of plaques 
(Amarenco et al., 1994). The risk of ischemic stroke in subjects with severe plaques 
was found to be increased by 3-fold compared to subjects without plaques (Hollander 
et al., 2002).  
 
1.5.1.4 Atrial fibrillation  
 
Even in the absence of other heart diseases, AF is associated with a 4- to 5-fold 
increased risk of ischemic stroke due to an embolism of stasis-induced thrombi 
forming in the left atrial appendage (Kannel and Benjamin, 2008). Moreover, one out 
of six strokes occurs in a patient with AF (Hart et al., 2004). Moreover, other studies 
have indicated that ischemic stroke associated with AF is almost twice as likely to be 
fatal than strokes not associated with AF, and AF is an independent predictor of 
mortality or severe functional deficits among survivors of ischemic stroke attack 
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(Kannel and Wolf, 2006; Nedeltchev et al., 2010). Furthermore, there is a vitally 
important opportunity for primary stroke prevention among patients with AF. For 
patients with AF who are classified as being at low risk of stroke, aspirin therapy 
alone is recommended; for patients at a high risk of stroke, an adjusted dose of 
warfarin, to the “target international normalized ratio (INR) range 2.0 to 3.0”, or 
other anticoagulants can provide the greatest protection against stroke (Singer et al., 
2008). 
  
1.5.1.5 Dyslipidemia 
 
Dyslipidemia has long been recognized as a risk factor for IHD, but the risk of stroke 
has become increasingly apparent over the past decade (Lewis and Segal, 2010). 
Dyslipidemia is defined as elevated levels of low-density lipoproteins (LDL > 130 
mg/dl) or triglycerides (>150 mg/dl), or decreased levels of high-density lipoproteins 
(HDL < 40 mg/dl) (Lloyd-Jones et al., 2010). Moreover, a recent meta-analysis of 24 
randomized trials that included 165,792 individuals showed that the reduction of 
LDL by 39 mg/dl led to a reduction in relative risk of stroke by 21.1% (p = 0.009) 
(Amarenco and Labreuche, 2009). This meta-analysis also showed that the incidence 
of all strokes was reduced by 18% by statin treatment  (p < 0.001) (Amarenco and 
Labreuche, 2009).   
 
1.5.1.6 Renal impairment 
 
Patients with renal impairment were associated with a greater risk of developing 
ischemic stroke (Nakayama et al., 2007; Kobayashi et al., 2009). Moreover, renal 
impairment is an important predictor of mortality in patients with a variety of 
cardiovascular diseases, including stroke (MacWalter et al., 2002; Sweileh, 2008). In 
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addition, a diagnosis of renal impairment has been linked to poorer medium-term and 
long-term outcomes following the occurrence of stroke, including increased rates of 
all-cause mortality (Tsagalis et al., 2009). These findings suggest that there are 
mechanisms in the pathogenesis of stroke that warrant additional investigation.  
 
1.5.1.7 Heart failure  
 
Heart failure (HF) represents an important health problem. Its incidence approaches 
10 per 1000 population after 65 years of age (Lloyd-Jones et al., 2010). The reported 
stroke risk rate in HF varies according to the study and the length of patient follow-
up: 1 to 29% of patients with dilated cardiomyopathy might have a stroke in 1 to 11 
years of follow-up compared to 0.8% to 4% during hospitalization and up to 3 years 
of follow-up (Witt et al., 2007). Moreover, pre-existing HF has been associated with 
a more severe type of ischemic stroke and with stroke mortality, both in the acute 
phase and in the first 3 months after the attack (Appelros et al., 2002). 
 
1.5.1.8 Smoking  
 
The Framingham Heart Study was among the first studies that evaluated the 
relationship between smoking, including the number of cigarettes smoked, and the 
effect of stopping, and the type of stroke (Wolf et al., 1988). This study identified 
cigarette smoking as a potent risk factor for ischemic stroke, and the relative risk of 
stroke in heavy smokers (> 40 cigarettes per day) was found to be twice than that of 
light smokers (< 10 cigarettes per day). Also, the reduction in the risk ratio was 
significant by 2 years after smoking cessation and it reached the level of a non-
smoker at 5 years (Wolf et al., 1988). Furthermore, smoking may contribute to 
increased stroke risk via both acute effects on generating a thrombus in 
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atherosclerotic arteries and chronic effects related to increased atherosclerosis 
(Burns, 2003). Impaired endogenous fibrinolysis, decreased blood flow in the brain, 
increased heart rate and increased blood pressure due to the vasoconstrictive effects 
of smoking are associated with lacunar stroke development (Jackson and Sudlow, 
2005). 
 
1.5.1.9 Left ventricular hypertrophy 
 
The increased mass of left ventricle is independently associated with the risk of 
ischemic stroke (Bikkina et al., 1994), although the mechanisms of the relationship 
between left ventricular hypertrophy (LVH) and ischemic stroke are not fully clear. 
One explanation is that large vessel disease promotes blood stasis in both the left 
ventricle and left atrium, increasing the chance of thrombus formation and the risk of 
embolic stroke (Allen and Bayraktutan, 2008). 
 
1.5.1.10 Obesity 
 
Abdominal obesity has been found to be an independent, potent risk factor for 
ischemic stroke, particularly the large vessel stroke subtype (Lu et al., 2006; Ohira et 
al., 2006b). Some studies have shown that abdominal obesity is related to endothelial 
dysfunction, a marker of atherosclerotic disease, and to hemorheological disorders 
such as hyperviscosity, hyperfibrinogenemia, reduced red cell deformability and 
erythrocyte aggregability (Carr and Brunzell, 2004; Wessel et al., 2004).  
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1.5.1.11 Carotid artery stenosis  
Carotid artery stenosis is a pathologic atherosclerotic narrowing of the extracranial 
carotid arteries (Smith et al., 2001). Patients with more than 70% stenosis in the 
carotid artery and a history of stroke or TIA are 6 times more risk of developing a 
recurrent stroke on the side of the stenosis compared to asymptomatic patients 
(Fatahzadeh and Glick, 2006). On the other hand, significant reduction in the risk of 
stroke has been obtained by surgical intervention extracranial carotid stenosis (Sacco, 
2001; Goldstein, 2003). In addition, aspirin therapy and modifications of risk factors 
are recommended for patients with asymptomatic carotid disease (Smith et al., 
2001). 
 
1.5.1.12 Elevated lipoprotein (a)  
 
Lipoprotein (a) is a low-density lipoprotein particle in which apolipoprotein B-100 is 
covalently linked to the glycoprotein apoprotein (a). Its structure is similar to LDL. 
Moreover, apoprotein (a) has a similar structure to plasminogen but it does not have 
its enzymatic activity. Therefore, it can inhibit fibrinolysis by binding to the catalytic 
complex of plasminogen, tissue plasminogen activator, and fibrin, leading to 
thrombosis (Hancock et al., 2003; Marcovina and Koschinsky, 2003).  
 
In addition, some population-based epidemiological studies found that lipoprotein (a) 
is associated with an increased risk of ischemic stroke (Milionis et al., 2006; Ohira et 
al., 2006a). It has been proposed that the use of niacin might prevent ischemic stroke 
in patients with high levels of lipoprotein (a), but its effectiveness has not been well 
established (Goldstein et al., 2011). 
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1.5.1.13 Von Willebrand factor  
 
The Von Willebrand factor (vWF) is a plasma glycoprotein and a mediator of platelet 
adhesion during endothelial insults via its spontaneous formation of strong bonds 
with the platelet glycoprotein 1b-IX-V complex, resulting in platelet aggregation and 
thrombus formation (Nishio et al., 2004). It has been shown that vWF levels were 
significantly higher in ischemic stroke patients, especially in the acute phase of all 
stroke subtypes (Kozuka et al., 2002). 
 
1.5.1.14 C-reactive protein (CRP) 
The C- reactive protein (CRP) is an acute-phase plasma protein produced by the liver 
and is considered as a molecular marker of the risk of stroke associated with 
inflammation (Elkind, 2010). The CRP has been demonstrated to predict disease 
progression and clinical adverse events in cerebrovascular circulation in apparently 
healthy subjects as well as in patients with established atherosclerosis. Moreover, 
CRP has also been shown to exacerbate ischemic necrosis (Rost et al., 2001; Elkind, 
2010). 
 
1.5.1.15 Homocysteine 
Homocysteine is a sulfur-containing amino acid derived from the conversion of 
methionine to cysteine (Kardesoglu et al., 2011). Elevated levels of homocysteine 
are often a consequence of deficiencies in some B vitamins, some rare hereditary 
diseases, or they can be drug induced (Bostom et al., 1999; Ntaios et al., 2009). 
Evidence has been accumulated to support the concept that an elevation in plasma 
homocysteine is a strong predictor for the incidence of and mortality from 
atherosclerosis, cardiovascular disease and ischemic stroke, and this graded 
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association was found to be independent of other traditional risk factors (Bostom et 
al., 1999; Tanne et al., 2003).  
 
1.5.1.16 Alcohol abuse  
Alcohol abuse can lead to some medical complications, including stroke (Patra et al., 
2010; Hillbom et al., 2011). It has been shown that heavy alcohol consumption can 
increase the relative risk of stroke subtypes, while light or moderate alcohol 
consumption may have a protective effect and reduce the risk of ischemic stroke 
(Patra et al., 2010). Heavy alcohol intake can lead to hypertension, hypercoagulation, 
reduced cerebral blood flow, and a greater risk of AF (Djousse et al., 2004; 
Mukamal, 2004). On the other hand, light to moderate alcohol intake can increase 
HDL, reduce platelet aggregation, and lower plasma fibrinogen concentration 
(Gaziano et al., 1993; Britton et al., 2009; Djousse et al., 2009). 
 
1.5.2 Non-modifiable risk factors 
 
1.5.2.1 Age 
 
Age is the most important non-modifiable risk factor for ischemic stroke (Rothwell 
et al., 2005a). Although ischemic stroke can affect individuals of different ages, the 
incidence and prevalence of this condition sharply increase with age (Goldstein et 
al., 2011). Moreover, the prevalence of cerebral infarction between the age of 55 and 
64 years was found to be nearly 11%. This prevalence increases to 22% between 65 
and 69 years of age, 28% between 70 and 74 years of age, 32% between 75 and 79 
years of age, 40% between 80 and 85 years of age, and 43% at more than 85 years 
old (Lloyd-Jones et al., 2010). Moreover, in the Northern Manhattan Stroke Study 
(NOMASS), which illustrated the relationship between age and ischemic stroke 
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subtypes, the majority of ischemic strokes in adult patients aged between 20 and 44 
years were cryptogenic (55%). Other subtypes were less common: lacunar (18%), 
intracranial atherosclerosis (9%), cardioembolic (6%) and extracranial 
atherosclerosis (6%). On the other hand, the incidence of cardioembolic stroke was 
found to be much greater in an age group older than 45 years, and a decrease in the 
incidence of cryptogenic stroke was also observed (Jacobs et al., 2002).  
 
It has been estimated that by the year 2025, the global population aged above 60 
years old may rise to 1.2 billion, which is double the number of people above that 
age in 1995 (Krug et al., 2002). This growth in the elderly population, together with 
the influence of aging on stroke, suggests that the incidence and economic costs of 
this disease will increase (Chen et al., 2010). 
 
1.5.2.2 Gender 
 
The incidence of stroke was found to be greater in males compared to females at 
younger ages, but not at very younger or much older ages (Kissela et al., 2004; 
Lloyd-Jones et al., 2010). Factors such as the use of oral contraceptives and 
pregnancy might contribute to the increased risk of stroke in young females 
(Baillargeon et al., 2005), and the earlier cardiac-related deaths in males might 
contribute to the relatively greater risk of stroke in older females. 
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1.5.2.3 Ethnic group  
 
Ethnic effects on disease risk can be difficult to be considered separately. Compared 
to European Americans, African Americans and some Hispanic Americans have 
higher rates of stroke incidence and mortality (White et al., 2005; Borrell and 
Crawford, 2009). Possible reasons for the higher stroke incidence and mortality rates 
in blacks compared to whites include a higher prevalence of hypertension, DM and 
obesity among the black population (Kurian and Cardarelli, 2007). In addition, a 
previous study regarding the incidence of stroke in Chinese, Malays and Indians in 
Singapore found in females aged < 65 years, there was a significantly greater rate of 
stroke incidence among the Malays than the Chinese (Heng et al., 2000). However, 
no significant differences regarding stroke prevalence among Singaporeans aged 50 
years and older (Venketasubramanian et al., 2005). 
 
1.6 Treatment of acute ischemic stroke 
1.6.1 Current management strategy  
 
Once a patient has arrived at the hospital and diagnosed with acute ischemic stroke, 
management serves two purposes: to reduce the burden of disability and mortality 
after the attack and to reduce the risk of recurrent stroke, which is referred to as 
secondary prevention. Acute treatment of ischemic stroke involves the control of 
physiological variables, strategies to reperfuse the ischemic area, and protection of 
the vulnerable ischemic penumbra using neuroprotective therapy (Adams et al., 
2007).  
All patients should be cared for in a dedicated acute stroke unit, which in itself saves 
lives and significantly improves functional outcomes (Langhorne et al., 2010). 
Furthermore, all patients with suspected stroke should undergo emergency brain 
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imaging to help confirm the diagnosis. The main choices of brain imaging are CT 
and MRI. An immediate brain scan enables rapid treatment initiation and improves 
stroke outcomes (Wardlaw et al., 2004). Non-contrast CT brain imaging is the most 
widely available test and has excellent sensitivity for detecting hemorrhage early 
after onset, while MRI has a similar sensitivity for detecting hemorrhage and a 
significantly greater sensitivity for detecting ischemia (Chalela et al., 2007).  
 
1.6.2 Control of physiological variables 
 
1.6.2.1 Control of blood pressure 
 
High blood pressure is found in nearly 80% of patients following acute stroke 
(Leonardi-Bee et al., 2002), which may result from the stress of the stroke, pain, 
previous hypertension, a full bladder, a physiological response to hypoxia, or 
increased intracranial pressure (Adams et al., 2007). It has been revealed that high 
blood pressure is independently associated with poor outcome (Willmot et al., 2004). 
However, a blood pressure elevation directly after an attack could represent a 
protective response, and subsequent falls in blood pressure can lead to infarct 
expansion because of impaired cerebrovascular autoregulation following acute stroke 
(Sare et al., 2009). The current guidelines suggest an early lowering of blood 
pressure in the presence of hypertensive encephalopathy, aortic dissection, severe 
cardiac failure and in cases where the blood pressure is extremely high (> 220 mmHg 
for systolic blood pressure or > 120 mmHg for diastolic blood pressure) (Chobanian 
et al., 2003; Adams et al., 2007; Goldstein et al., 2011).   
There are a growing number of pharmacological treatment choices for patients with 
hypertension. However, the choice of a certain antihypertensive drug class is affected 
by many factors, including the presence of co-morbid conditions (Chobanian et al., 
